GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » ROE %

AKBLF (Alk-Abello AS) ROE % : 17.21% (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello AS ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Alk-Abello AS's annualized net income for the quarter that ended in Sep. 2024 was $126.2 Mil. Alk-Abello AS's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $733.3 Mil. Therefore, Alk-Abello AS's annualized ROE % for the quarter that ended in Sep. 2024 was 17.21%.

The historical rank and industry rank for Alk-Abello AS's ROE % or its related term are showing as below:

AKBLF' s ROE % Range Over the Past 10 Years
Min: -5.26   Med: 7.23   Max: 16.71
Current: 16.71

During the past 13 years, Alk-Abello AS's highest ROE % was 16.71%. The lowest was -5.26%. And the median was 7.23%.

AKBLF's ROE % is ranked better than
93.95% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs AKBLF: 16.71

Alk-Abello AS ROE % Historical Data

The historical data trend for Alk-Abello AS's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS ROE % Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.55 0.83 6.37 8.70 11.67

Alk-Abello AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.89 12.88 20.28 16.65 17.21

Competitive Comparison of Alk-Abello AS's ROE %

For the Biotechnology subindustry, Alk-Abello AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's ROE % distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's ROE % falls into.



Alk-Abello AS ROE % Calculation

Alk-Abello AS's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=71.107/( (567.857+650.641)/ 2 )
=71.107/609.249
=11.67 %

Alk-Abello AS's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=126.228/( (709.444+757.071)/ 2 )
=126.228/733.2575
=17.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Alk-Abello AS  (OTCPK:AKBLF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=126.228/733.2575
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(126.228 / 781.78)*(781.78 / 1040.1115)*(1040.1115 / 733.2575)
=Net Margin %*Asset Turnover*Equity Multiplier
=16.15 %*0.7516*1.4185
=ROA %*Equity Multiplier
=12.14 %*1.4185
=17.21 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=126.228/733.2575
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (126.228 / 167.312) * (167.312 / 182.196) * (182.196 / 781.78) * (781.78 / 1040.1115) * (1040.1115 / 733.2575)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7544 * 0.9183 * 23.31 % * 0.7516 * 1.4185
=17.21 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Alk-Abello AS ROE % Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

From GuruFocus

Q4 2021 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2023 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2020 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2022 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2021 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2023 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2021 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2020 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2023 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2019 ALK-Abello A/S Earnings Call Transcript

By GuruFocus Research 02-12-2024